Previous studies reported similar poor survival as a significant clinical outcome and observed a short relapsed period within 1 year in all of the adult BCP-ALL patients concurrent with the BCR-ABL fusion gene and CDKN2 deletion [5, 31]. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.